118 related articles for article (PubMed ID: 35259675)
1. Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model.
Tobias J; Drinić M; Högler S; Ambroz K; Baier K; Kodajova P; Tomasich E; Berghoff AS; Schmid A; Garner-Spitzer E; Kenner L; Kundi M; Zielinski CC; Wiedermann U
Transl Oncol; 2022 May; 19():101378. PubMed ID: 35259675
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.
Tobias J; Högler S; Raigel M; Lin DS; Chao Y; Kenner L; Garner-Spitzer E; Yavrom S; Ede NJ; Zielinski CC; Kundi M; Wiedermann U
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203458
[TBL] [Abstract][Full Text] [Related]
3. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice.
Özverel CS; Uyanikgil Y; Karaboz İ; Nalbantsoy A
Immunopharmacol Immunotoxicol; 2020 Aug; 42(4):346-357. PubMed ID: 32515626
[TBL] [Abstract][Full Text] [Related]
5. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
[TBL] [Abstract][Full Text] [Related]
6. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
[TBL] [Abstract][Full Text] [Related]
7. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.
Seavey MM; Pan ZK; Maciag PC; Wallecha A; Rivera S; Paterson Y; Shahabi V
Clin Cancer Res; 2009 Feb; 15(3):924-32. PubMed ID: 19188163
[TBL] [Abstract][Full Text] [Related]
8. Vaccination against Her-2/neu, with focus on peptide-based vaccines.
Tobias J; Garner-Spitzer E; Drinić M; Wiedermann U
ESMO Open; 2022 Feb; 7(1):100361. PubMed ID: 35026721
[TBL] [Abstract][Full Text] [Related]
9. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
10. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.
Chen Y; Xie Y; Chan T; Sami A; Ahmed S; Liu Q; Xiang J
Cancer Gene Ther; 2011 Jul; 18(7):489-99. PubMed ID: 21566669
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model.
Kaumaya PTP; Guo L; Overholser J; Penichet ML; Bekaii-Saab T
Oncoimmunology; 2020 Oct; 9(1):1818437. PubMed ID: 33117602
[TBL] [Abstract][Full Text] [Related]
13. LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.
Rosenthal KS; Stone S; Koski G; Zimmerman DH
J Immunol Res; 2017; 2017():3613505. PubMed ID: 28459074
[TBL] [Abstract][Full Text] [Related]
14. Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.
Ede NJ; Good AJ; Tobias J; Garner-Spitzer E; Zielinski CC; Wiedermann U
Front Oncol; 2022; 12():939356. PubMed ID: 36578947
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Zaks TZ; Rosenberg SA
Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
[TBL] [Abstract][Full Text] [Related]
17. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
Disis ML; Gooley TA; Rinn K; Davis D; Piepkorn M; Cheever MA; Knutson KL; Schiffman K
J Clin Oncol; 2002 Jun; 20(11):2624-32. PubMed ID: 12039923
[TBL] [Abstract][Full Text] [Related]
18. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
19. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status.
Grupka NL; Lear-Kaul KC; Kleinschmidt-DeMasters BK; Singh M
Arch Pathol Lab Med; 2004 Sep; 128(9):974-9. PubMed ID: 15335267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
